XHXue Han

Xue Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xue Han has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The in vivo inhibitory function of the MHC-I α3 domain–CD8α interaction

    by Juanjuan Zhao, Lawrence Feng, Yang Xu, Kareem Alsbei, Jun Wang, Tiffany Zhou, Qipeng Zhan, Shiya Sun, Eric Hong, Lingbin Meng, et al.

    The interaction between the Major Histocompatibility Complex Class I (MHC-I) α3 domain and CD8α has classically been viewed as a positive coreceptor interaction that stabilizes TCR signaling during antigen recognition. However, its physiological function in mature peripheral CD8+ T cells in vivo remains incompletely understood. Here, we identify the MHC-I α3 domain–CD8α interaction as a previously unrecognized inhibitory pathway that tonically restrains peripheral CD8+ T-cell activation and maintains T-cell tolerance in vivo. Antibody-mediated disruption of the MHC-I α3 domain–CD8α interaction induced spontaneous activation of peripheral CD8+ T cells without impairing their survival, lowered the threshold for antigen-induced activation, and enhanced responsiveness to cognate peptide stimulation. In peptide-induced OT-I T-cell anergy models, blockade of either H-2D b or H-2K b α3 domain interactions with CD8α prevented the induction of anergy and restored responsiveness of previously anergic T cells. Notably, blockade of the H-2K b α3 domain enhanced OT-I responses despite simultaneously disrupting the classical positive coreceptor interaction within the TCR–peptide–MHC complex, indicating that tonic inhibitory signaling mediated by the MHC-I α3 domain predominates under these conditions. Together, these findings redefine the classical MHC-I–CD8α interaction as a bidirectional pathway that not only supports antigen recognition but also imposes tonic inhibitory control over peripheral CD8+ T cells. These results identify the MHC-I α3 domain–CD8α axis as a potential target for reversing T-cell tolerance and enhancing antitumor or antiviral immunity.

  • Open Access

    A Rare Case of Aleukemic B‐Cell Acute Lymphoblastic Leukemia Presenting as Rapidly Progressive Severe Low Back Pain in an Adolescent With a History of Anxiety and Depression

    by TingTing Huang, Lingbin Meng, Linghua Zheng, Xue Han, Ephraim Ansa-Addo, Feng Hong

    Introduction: Musculoskeletal complaints are a frequent cause of pediatric emergency visits. While adolescent back pain is typically benign, it can occasionally signal underlying malignancy. Distinguishing organic pathology from functional disorders is particularly challenging in patients with pre‐existing psychiatric comorbidities, leading to potential diagnostic delays. Case Presentation: We report a 17‐year‐old female with a history of anxiety and depression presenting with two weeks of severe lumbar pain and progressive gait difficulty. Initial evaluations, including spinal radiography and complete blood count, were unremarkable. Her symptoms were initially attributed to musculoskeletal strain. However, as symptoms persisted, her psychiatric history may have contributed to diagnostic overshadowing when psychogenic factors were subsequently considered. Rapid functional deterioration prompted further workup, revealing markedly elevated inflammatory markers and lactate dehydrogenase (LDH). Magnetic resonance imaging (MRI) demonstrated diffuse marrow signal abnormalities. Subsequent bone marrow biopsy confirmed B‐cell acute lymphoblastic leukemia (B‐ALL). Cytogenetics analysis showed a normal karyotype. Discussion: ALL rarely initially presents with isolated back pain in adolescents, commonly resulting in delayed diagnosis. This delay can be further exacerbated by diagnostic overshadowing, a cognitive bias in which a patient’s psychiatric history leads clinicians to prematurely attribute severe somatic symptoms to functional or psychogenic etiologies. This case also highlights that early leukemic bone marrow infiltration may occur despite normal peripheral blood counts and unrevealing plain radiographs. Therefore, persistent symptoms and rapid clinical deterioration despite initially reassuring investigations should prompt reconsideration of the diagnosis and additional evaluation, including selected laboratory studies, such as LDH and inflammatory markers, and advanced imaging (MRI) when clinically indicated. Conclusion: This case underscores the importance of maintaining a broad differential diagnosis and looking beyond psychiatric comorbidities when evaluating adolescents with persistent or nocturnal back pain accompanied by rapid functional decline, despite initial reassuring radiographs and hematologic studies. In such patients, additional laboratory assessment and MRI may be considered when the clinical course is disproportionate to an expected musculoskeletal injury, helping to identify serious underlying pathology and reduce the risk of diagnostic delay.

  • Open Access

    PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

    by Tae Kon Kim, Xue Han, Qianni Hu, Esten N. Vandsemb, Carly M. Fielder, Junshik Hong, Kwang Woon Kim, Emily F. Mason, R. Skipper Plowman, Jun Wang, et al.

    Acute myeloid leukemia (AML) presents a pressing medical need in that it is largely resistant to standard chemotherapy as well as modern therapeutics, such as targeted therapy and immunotherapy, including anti–programmed cell death protein (anti-PD) therapy. We demonstrate that programmed death-1 homolog (PD-1H), an immune coinhibitory molecule, is highly expressed in blasts from the bone marrow of AML patients, while normal myeloid cell subsets and T cells express PD-1H. In studies employing syngeneic and humanized AML mouse models, overexpression of PD-1H promoted the growth of AML cells, mainly by evading T cell–mediated immune responses. Importantly, ablation of AML cell-surface PD-1H by antibody blockade or genetic knockout significantly inhibited AML progression by promoting T cell activity. In addition, the genetic deletion of PD-1H from host normal myeloid cells inhibited AML progression, and the combination of PD-1H blockade with anti-PD therapy conferred a synergistic antileukemia effect. Our findings provide the basis for PD-1H as a potential therapeutic target for treating human AML.


  • Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes

    by Matthew D. Vesely, Michal Kidacki, Patricia Gaule, Swati Gupta, Nay Nwe Nyein Chan, Xue Han, Jacky T. Yeung, Lieping Chen


  • Open Access

    Supplementary Data from A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

    by Miguel F. Sanmamed, Xinxin Nie, Shruti S. Desai, Franz Villaroel-Espindola, Ti Badri, Dejian Zhao, Anthony W. Kim, Lan Ji, Tianxiang Zhang, Edward Quinlan, et al.

  • Open Access

    Supplementary Tables from A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

    by Miguel F. Sanmamed, Xinxin Nie, Shruti S. Desai, Franz Villaroel-Espindola, Ti Badri, Dejian Zhao, Anthony W. Kim, Lan Ji, Tianxiang Zhang, Edward Quinlan, et al.

  • Open Access

    Supplementary Figures from A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

    by Miguel F. Sanmamed, Xinxin Nie, Shruti S. Desai, Franz Villaroel-Espindola, Ti Badri, Dejian Zhao, Anthony W. Kim, Lan Ji, Tianxiang Zhang, Edward Quinlan, et al.

  • Open Access

    Data from A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

    by Miguel F. Sanmamed, Xinxin Nie, Shruti S. Desai, Franz Villaroel-Espindola, Ti Badri, Dejian Zhao, Anthony W. Kim, Lan Ji, Tianxiang Zhang, Edward Quinlan, et al.

  • Open Access

    Supplementary Data from A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

    by Miguel F. Sanmamed, Xinxin Nie, Shruti S. Desai, Franz Villaroel-Espindola, Ti Badri, Dejian Zhao, Anthony W. Kim, Lan Ji, Tianxiang Zhang, Edward Quinlan, et al.

  • Open Access

    Data from A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

    by Miguel F. Sanmamed, Xinxin Nie, Shruti S. Desai, Franz Villaroel-Espindola, Ti Badri, Dejian Zhao, Anthony W. Kim, Lan Ji, Tianxiang Zhang, Edward Quinlan, et al.

    Specific mechanisms by which tumor-infiltrating lymphocytes (TIL) become dysfunctional remain poorly understood. Here, we employed a two-pronged approach using single-cell mass cytometry and tissue imaging technologies to dissect TILs from 25 patients with resectable and 35 patients with advanced non–small cell lung cancer (NSCLC). We identified a burned-out CD8+ TIL subset (Ebo) that specifically accumulated within the tumor microenvironment (TME) but not in adjacent nontumoral tissues. Ebo showed the highest expression of proliferation and activation markers but produced the lowest amount of IFNγ and were the most apoptotic CD8+ TIL subset. Using a humanized patient-derived tumor xenograft model, we demonstrated that Ebo expansion occurred within the TME in a PD-1/B7-H1 pathway-dependent manner. Ebo abundance in baseline tumor tissues was associated with resistance to anti-PD therapy in patients with NSCLC. Our study identifies a dysfunctional TIL subset, with distinct features from previously described exhausted T cells, and implies strategies to overcome immunotherapy resistance.Significance:We identified a highly proliferative, overactivated, and apoptotic dysfunctional CD8+ tumor-infiltrating subpopulation that is functionally distinct from previously described exhausted T cells. This population is expanded in lung cancer tissues in a PD-1/B7-H1-dependent manner, and its abundance is associated with resistance to cancer immunotherapy, thus becoming a potential tissue biomarker.This article is highlighted in the In This Issue feature, p. 1601